The Financial Times reports today that the private equity firms that took Hologic private are looking to sell one of its businesses.
Funds managed by Blackstone and TPG closed their acquisition of the Marlborough, Massachusetts-based company in April. The deal took Hologic private, with analysts labeling it the “far and away the largest” private equity take-out in medical devices this year.
According to the report today, which cites people familiar with the matter, Blackstone and TPG now hope to fetch more than $4 billion for the Hologic Surgical unit. The report states that the firms are working with advisers on the sale of the business, which makes surgical equipment used by gynecologists.
Hologic’s annual report from late 2025 says the company’s surgical products include its MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Fluent fluid management system, Sonata transcervical radiofrequency ablation system, Acessa ProVu laparoscopic radiofrequency ablation system, CoolSeal vessel sealing portfolio, and JustRight surgical stapler.
FT reports that the private equity groups are seeking to pay down debt and repay investors from the acquisition. The deal included significant minority investments from a wholly owned subsidiary of the Abu Dhabi Investment Authority and an affiliate of GIC.
According to Reuters, the private equity firms are grappling with “strains in private credit” making their way into adjacent private equity markets. That report claims firms want to find ways to get cash back in the hands of their investors as a result.
Hologic is making these potential portfolio moves under new leadership. CEO Steve MacMillan retired upon the completion of the acquisition, paving the way for former Baxter head José (Joe) E. Almeida to take over the corner office and lead the now-private company.
